US EditionFreya Pharma launches phase 2 study of therapy for female sexual dysfunction - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Freya Pharma launches phase 2 study of therapy for female sexual dysfunction - Pharmafile
Freya Pharma Solutions has announced the initiation of a phase 2 study evaluating its Lybrido to treat female sexual interest/arousal disorder (FSIAD). Conducted at Chaim Sheba Medical Center, Israel, the study will test two dose combinations of sublingual testosterone and oral sildenafil to assess their physiological effects on genital blood flow. Led by principal investigator […] The post Freya Pharma launches phase 2 study of therapy for fema…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
